PMID- 27917698 OWN - NLM STAT- MEDLINE DCOM- 20170918 LR - 20211204 IS - 1557-8534 (Electronic) IS - 1547-3287 (Linking) VI - 26 IP - 6 DP - 2017 Mar 15 TI - Tetramethylpyrazine Protects Against Glucocorticoid-Induced Apoptosis by Promoting Autophagy in Mesenchymal Stem Cells and Improves Bone Mass in Glucocorticoid-Induced Osteoporosis Rats. PG - 419-430 LID - 10.1089/scd.2016.0233 [doi] AB - Glucocorticoid-induced osteoporosis (GIOP) is a widespread clinical complication due to the common use of glucocorticoids. Excess glucocorticoids induce apoptosis of bone marrow-derived mesenchymal stem cells (BMSCs), which have been shown to play an increasingly important role in the pathogenesis and therapy of osteoporosis. Tetramethylpyrazine (TMP), an extract from one of the most recognized herbs in traditional Chinese medicine (Chuanxiong), has been reported to have antiapoptotic properties. In this study, we tested whether TMP protects rat BMSCs following exposure to glucocorticoids in vitro and in vivo. We treated BMSCs with different concentrations of TMP (50, 100, or 200 muM) and exposed them to 10(-6) M dexamethasone (Dex) for 48 h in vitro. Our data showed that TMP inhibited Dex-induced cytotoxicity and protected BMSCs from apoptosis. Interestingly, further results demonstrated that TMP prevented apoptosis in BMSCs by promoting autophagy in an AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) pathway-dependent manner. In addition, calcein fluorescence double labeling and microcomputed tomography scanning indicated that 12 weeks of TMP administration augmented bone formation and protected trabecular bone mass in GIOP rats. We also discovered that first-passage BMSCs isolated from the TMP treatment group had a lower rate of apoptosis and a higher light chain 3 (LC3)-II/LC3-I ratio than the GIOP group. Our findings demonstrate for the first time that TMP can protect BMSCs from exposure to excess glucocorticoids by promoting autophagy through AMPK/mTOR pathway and might be an effective agent for the prevention and treatment of GIOP. FAU - Wang, Long AU - Wang L AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Zhang, Hong-Yang AU - Zhang HY AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Gao, Bo AU - Gao B AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Shi, Jun AU - Shi J AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Huang, Qiang AU - Huang Q AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Han, Yue-Hu AU - Han YH AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Hu, Ya-Qian AU - Hu YQ AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Lu, Wei-Guang AU - Lu WG AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Zhao, Zhuo-Jie AU - Zhao ZJ AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Liu, Bao-Hua AU - Liu BH AD - 2 Health Science Center, Shenzhen University , Shenzhen, People's Republic of China . FAU - Jie, Qiang AU - Jie Q AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Yang, Liu AU - Yang L AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . FAU - Luo, Zhuo-Jing AU - Luo ZJ AD - 1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University , Xi'an, People's Republic of China . LA - eng PT - Journal Article DEP - 20170104 PL - United States TA - Stem Cells Dev JT - Stem cells and development JID - 101197107 RN - 0 (Glucocorticoids) RN - 0 (Protective Agents) RN - 0 (Pyrazines) RN - 7S5I7G3JQL (Dexamethasone) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - V80F4IA5XG (tetramethylpyrazine) SB - IM MH - AMP-Activated Protein Kinases/metabolism MH - Animals MH - Apoptosis/*drug effects MH - Autophagy/*drug effects MH - Bone and Bones/drug effects/*pathology MH - Dexamethasone MH - Glucocorticoids/*adverse effects MH - Mesenchymal Stem Cells/*cytology/drug effects/metabolism MH - Organ Size/drug effects MH - Osteogenesis/drug effects MH - Osteoporosis/*chemically induced/*drug therapy/pathology MH - Protective Agents/pharmacology/therapeutic use MH - Pyrazines/pharmacology/*therapeutic use MH - Rats, Sprague-Dawley MH - Signal Transduction/drug effects MH - TOR Serine-Threonine Kinases/metabolism OTO - NOTNLM OT - autophagy OT - bone marrow-derived mesenchymal stem cells OT - glucocorticoids OT - osteoporosis OT - tetramethylpyrazine EDAT- 2016/12/06 06:00 MHDA- 2017/09/19 06:00 CRDT- 2016/12/06 06:00 PHST- 2016/12/06 06:00 [pubmed] PHST- 2017/09/19 06:00 [medline] PHST- 2016/12/06 06:00 [entrez] AID - 10.1089/scd.2016.0233 [doi] PST - ppublish SO - Stem Cells Dev. 2017 Mar 15;26(6):419-430. doi: 10.1089/scd.2016.0233. Epub 2017 Jan 4.